
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is a promising biotechnology company, with a pioneering protein degradation platform and a strong pipeline of potential therapies for oncology and neurology indications. The company's partnerships with major pharmaceutical companies, such as Pfizer and Novartis, provide further validation of its approach and potential commercial leverage. With a new CEO in place, focused on building out each area while narrowing the overall portfolio, and a potentially cleaner path to approval for its lead program in PSP, Arvinas has the potential for significant growth and success. Of course, as with any clinical-stage biotechnology company, there are risks involved, including unexpected clinical trial outcomes and competition, but the company's value potential outweighs these risks, making it an attractive investment opportunity.
Bears say
Arvinas is facing tough competition in the market from Biogen's BIIB122 drug, which has so far shown a more promising reduction of LRRK2 protein levels. Despite initial promising biomarker data and a clean safety profile for Arvinas's ARV-102, market credit is unlikely to come until clinical benefit is demonstrated and a successful phase 2b LUMA result is achieved by BIIB.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares